meta|evidence COVID-19

Living systematic review and meta-analysis

adjuvant therapies
anti-inflammatoty and immuno-therapy
antiandrogenic
antiviral and associated therapy
control
Drugs for acid related disorders
miscellaneous
Oral antidiabetic drugs
Renin-angiotensin-system-acting agents
angiotensin converting enzyme inhibitors (ACEIs)
angiotensin receptor blockers (ARBs)
losartan
angiotensin-(1-7)
continuation of ACEI/ARB
discontinuation of ACEI/ARB
RAS blocker withdrawal
rhACE2
vaccines
Vitamins

potential COVID-19 treatments
control
placebo
standard of care
miscellaneous
calcium channel blocker
Renin-angiotensin-system-acting agents
continuation of ACEI/ARB

All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
secondary prevention

Studies
Mapping
Meta-analysis
Excluded

Study		Exclusion reasons	Remarks	Reference(s)
Mehra, 2020	retrospective cohort (claims database)	other	paper retracted	NEJM June 4, 2020 10.1056/NEJMc2021225 Mehra MR et al. NEJM 10.1056/NEJMoa2007621

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -